We have used GABBRIOMYCINA to treat cases of anergic diffuse cutaneous leishmaniasis (ADCL) caused by Leishmania (Leishmania) amazonensis. There was a definite clinical improvement but the cure was not definitive. The response was progressively poorer when the treatment was repeated. Auditory secondary complications were detected.